Skip to main content
39°
Partly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
Contact Us
Subscribe
News
East Greenwich Pendulum
Kent County Daily Times
Narragansett Times
NK Standard-Times
Sports
Features
Special Sections
Local Guide
Local Events
Markets & Stocks
Weather
League of Women Voters SRI
League of Women Voters WS
Classifieds
Place ad
Legal Notices
Place Kent Legal
Place SRI Class Legal
Search SRI Legals
Search Kent Legals
Obituaries
Subscribe
E-Edition
Community Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
103.12
+1.50 (+1.48%)
Official Closing Price
Updated: 7:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Merck & Co
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
96
97
Next >
The Top 3 Dow Stocks to Buy in March 2024
March 04, 2024
Play defense with these top Dow stocks to buy as the market takes a breather from the 20% rally that started in November 2023.
Via
InvestorPlace
Topics
Stocks
Exposures
US Equities
Merck to Participate in the Leerink Partners Global Biopharma Conference 2024
March 04, 2024
From
Merck & Co., Inc.
Via
Business Wire
3 Magnificent Growth Stocks to Buy in March
March 02, 2024
These three stocks have two important common denominators: the same industry and tremendous growth prospects.
Via
The Motley Fool
Apple Sinks After Wall Street Titan Pulls Magnificent 7 Stock From Conviction List
March 01, 2024
Goldman Sachs is removing Apple from its Conviction List of buy-rated stocks. Looking at the potential reasons why and who replaced the tech giant.
Via
Benzinga
Critical Insights From Merck & Co Analyst Ratings: What You Need To Know
February 29, 2024
Via
Benzinga
Analyzing Merck & Co In Comparison To Competitors In Pharmaceuticals Industry
February 28, 2024
Via
Benzinga
Behind the Scenes of Merck & Co's Latest Options Trends
February 26, 2024
Via
Benzinga
What the Options Market Tells Us About Merck & Co
February 15, 2024
Via
Benzinga
7 Timeless Stocks to Invest in for 2024
March 01, 2024
These are attractive timeless stocks to buy as they represent quality companies with the potential to deliver healthy total returns.
Via
InvestorPlace
A Bull Market Is Here: 2 Magnificent Stocks Down 80% to Buy Right Now
February 29, 2024
The futures for these two beaten-down stocks could be brighter than their recent pasts.
Via
The Motley Fool
Gynecology Plays A Pivotal Role In Colorectal and Endometrial Cancer Screening
February 28, 2024
When it comes to cancer, one cannot overestimate the importance of early detection. Especially when it comes to colorectal and endometrial cancer that even big pharma companies don’t have a good track...
Via
Benzinga
3 Long-Term Winners from Charles Schwab’s Top Picks
February 27, 2024
Explore the growth and resilience of long-term stocks Microsoft, Merck and Veralto in the latest Charles Schwab stocks portfolio update.
Via
InvestorPlace
For those who appreciate value investing, NYSE:MRK is a compelling option with its solid fundamentals.
February 27, 2024
Don't overlook MERCK & CO. INC. (NYSE:MRK)—it's a hidden gem with strong fundamentals and an attractive price tag.
Via
Chartmill
Exploring The Competitive Space: Merck & Co Versus Industry Peers In Pharmaceuticals
February 14, 2024
Via
Benzinga
Merck to Participate in the TD Cowen 44th Annual Health Care Conference
February 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Why Is Cancer-Focused NGM Biopharmaceuticals Stock Trading Lower On Monday?
February 26, 2024
Explore NGM Bio's acquisition news by The Column Group at $1.55/share, an 80% premium. Learn about the recent Phase 1b study findings.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
February 26, 2024
Via
Benzinga
3 Top Pharma Stocks for Investors Betting on a Biotech Boom
February 26, 2024
Pharma stocks offer phenomenal returns when their drug gets approved. Here are three stocks that could soar in 2024.
Via
InvestorPlace
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy as Neoadjuvant Treatment, Then Continued as Monotherapy as Adjuvant Treatment, for the Treatment of Resectable NSCLC at High Risk of Recurrence
February 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
3 Undervalued Small-Cap Stocks to Add to Your Must-Buy List
February 22, 2024
Undervalued small-cap stocks are great for investors seeking options for upside potential, typically at a cheap share price.
Via
InvestorPlace
Outdoing Cancer Requires Pharma To Go Beyond Merely Revolutionizing Existing Treatment
February 22, 2024
Pfizer Inc (NYSE: PFE) is among the many pharmaceutical companies that turned to oncology in response to sinking demand for its COVID-19 products and near patent expiration dates for its several...
Via
Benzinga
Topics
Intellectual Property
Exposures
COVID-19
Intellectual Property
2 Monster Stocks to Buy Without Any Hesitation
February 22, 2024
Investors can sleep easy at night with these stocks in their portfolios.
Via
The Motley Fool
MAIA Biotechnology: Undervalued With Eye-Popping Cancer Data And Partnership Potential
February 22, 2024
MAIA Biotechnology, a biotechnology company developing innovative cancer treatments, has seen its stock drift downwards for the past months.
Via
Talk Markets
FDA Grants Priority Review to Merck's Application for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Primary Advanced or Recurrent Endometrial Carcinoma
February 20, 2024
From
Merck & Co., Inc.
Via
Business Wire
Recession's Shadow Casts Doubt On Soft Landing: Safeguard Your Portfolio With These Stocks
February 16, 2024
Via
Benzinga
Topics
Economy
Exposures
Economy
3 Inflation-Proof Stock Picks Following Tuesday’s CPI Report
February 15, 2024
Discover the strength of inflation-proof stocks through these investment picks, as they offer attractive yields and promising growth.
Via
InvestorPlace
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
EQNX::TICKER_START (NASDAQ:TNXP),(NYSE:PFE),(NYSE:LLY),(NYSE:ABBV),(NYSE:MRK) EQNX::TICKER_END
Via
FinancialNewsMedia
Global Fibromyalgia Treatment Market Expected to Reach $4.6 billion by 2032
February 15, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Drivers And Stock Pickers
February 13, 2024
As opposed to drivers who overestimate themselves, we seek to be above-average stock pickers by doing the things that most professional investors struggle with, like being courageous and patient.
Via
Talk Markets
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
< Previous
1
2
...
14
15
16
17
18
19
20
21
22
...
96
97
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.